About Mibiome Therapeutics Llp
Data last updated: 06 February 2026
Mibiome Therapeutics Llp is a limited liability partnership company based in Jogeshwart West Mumbai, Maharashtra, India, recognised as a startup by DPIIT. It specialises in service-based operations, a part of the broader business services sector. Incorporated on 16 May 2019, the LLP has been in operation for over 7 years.
Registered with ROC Mumbai under LLPIN AAP-3186.
Capital: a total obligation of contribution of ₹1 Lakh. It is led by designated partners Gautam Das and Ravi Ashwin Shroff.
Accounts filed on 31 March 2025. Office: Flexcel Park C Wing 2Nd Floor S. V. Road Near 24 Karat Multiplex, Jogeshwart West Mumbai, Maharashtra, India – 400102.
The LLP is associated with 2 brands - Anshul Specialty Molecules, Mibiome Therapeutics.
For more details, the LLP can be reached via its website mibiome.com.
-
Email**************
-
Telephone**************
-
Website**************
-
Social Media
-
Registered AddressFlexcel Park C Wing 2Nd Floor S. V. Road Near 24 Karat Multiplex, Jogeshwart West Mumbai, Maharashtra, India – 400102
-
IndustryBusiness Services, Other Services
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Associated Brands with Mibiome Therapeutics Llp
Mibiome Therapeutics Llp operates two associated brands: Anshul Specialty Molecules and miBiome Therapeutics. These brands represent Mibiome Therapeutics Llp's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Produces high-quality specialty chemicals for APIs, flavors, fragrances, and custom synthesis. | anshulchemicals.com | |
| Offers genomic sequencing, consulting, and analytics for research purposes. | mibiome.com |
Competitors & Alternatives of Mibiome Therapeutics Llp
Brands and companies operating in the same space as Mibiome Therapeutics Llp include Laurus Labs, Symbiotec, BGI and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Laurus Labs
|
Pharmaceutical and biotechnology company | Hyderabad, India, India | 2005 |
Symbiotec
|
Non-sterile steroid hormone-based APIs and intermediates are manufactured. | Indore, India, India | 2002 |
BGI
|
BGI is engaged in genomics and precision medicine solutions. | Shenzhen, China, China | 1999 |
Genewiz
|
Genomic services are provided for the life sciences industry. | South Plainfield, United States, United States | 1999 |
Beijing Biostar Technologies
|
APIs, intermediates, and biochemical reagents are developed and manufactured. | Beijing, China, China | 2002 |
Macrogen
|
Next-generation sequencing and genomics services are provided globally. | Seoul, South Korea, South Korea | 1997 |
Sterling Pharma Solutions
|
Contract development, manufacturing, and analytical services for APIs are offered. | Dudley, United Kingdom, United Kingdom | 2016 |
Provepharm Life Solutions
|
APIs and drug products are developed and valorized in pharmaceuticals. | Marseille, France, France | 1998 |
Hikal
|
APIs and intermediates are produced via custom synthesis and research. | Mumbai, India, India | 1988 |
CosmosID
|
Next-generation sequencing technologies for microorganism detection are developed. | Rockville, United States, United States | 2008 |
Designated Partners of Mibiome Therapeutics Llp
Mibiome Therapeutics Llp is currently managed by 2 designated partners, with 2 former designated partners having served the organization. The current Designated Partners play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Gautam Das | Designated Partner | 14 Nov 2020 | 5 Years 7 Months | Current |
|
Ravi Ashwin Shroff
Also directs:
Nextgen Sequensale Llp, Transpek Industry Limited, Excel Industries Limited and 5 more
|
Designated Partner | 16 May 2019 | 7 Years 1 Months | Current |
Financials of Mibiome Therapeutics Llp FY 2025 filings available
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Charges & Borrowings Mibiome Therapeutics Llp
Mibiome Therapeutics Llp does not have any charges (loans) registered with the Registrar of Companies.
Employees and EPFO Compliance at Mibiome Therapeutics Llp
View historical data on people associated with Mibiome Therapeutics Llp, including employment history and EPFO contributions.
Employee Count & EPFO Data of Mibiome Therapeutics Llp
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Mibiome Therapeutics Llp
GSTIN & GST Filing Data of Mibiome Therapeutics Llp
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Mibiome Therapeutics Llp
Credit Ratings, Legal Cases & Regulatory Alerts of Mibiome Therapeutics Llp
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Mibiome Therapeutics Llp
MSME Payment Delays by Mibiome Therapeutics Llp
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Mibiome Therapeutics Llp
Subsidiaries & Group Companies of Mibiome Therapeutics Llp
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Mibiome Therapeutics Llp with ownership details.
MCA Filings & Documents of Mibiome Therapeutics Llp
MCA Filings & Documents of Mibiome Therapeutics Llp
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Mibiome Therapeutics Llp
Frequently Asked Questions about Mibiome Therapeutics Llp
Mibiome Therapeutics Llp is an active limited liability partnership in the business services sector based in Jogeshwart West Mumbai, Maharashtra, India. It was incorporated on 16 May 2019 (7+ years old) and is registered under LLPIN AAP-3186.
The current designated partners of Mibiome Therapeutics Llp are:
The primary industry of Mibiome Therapeutics Llp is business services. The LLP specifically operates in other services. The LLP is currently active in this sector.
Yes, Mibiome Therapeutics Llp is recognised as a startup by the Department for Promotion of Industry and Internal Trade (DPIIT).
Mibiome Therapeutics Llp can be reached at the registered office: Flexcel Park C Wing 2Nd Floor S. V. Road Near 24 Karat Multiplex, Jogeshwart West Mumbai, Maharashtra, India – 400102, or through the website mibiome.com.
The total obligation of contribution is ₹1 Lakh.